Search

Objective: To investigate the relationship between the expression of human telomerase reverse transcriptase(hTERT) and metastasis tumor associated protein 1(MTA1) and the clinicopathological characteristics and prognosis of esophageal cancer. Methods: Selected 80 patients with esophageal cancer from January 2015 to October 2016. The levels of hTERT and MTA1 in cancer tissues and adjacent tissues were detected by immunohistochemistry, and the relationship between hTERT and MTA1 and clinicopathological features and their expression were analyzed. All patients were followed up for 36 months to observe the survival of patients with different expression of hTERT and MTA1, the relationship between the expression of hTERT and MTA1 and the prognosis was analyzed. Result: The positive rates of hTERT and MTA1 in esophageal carcinoma were significantly higher than those in adjacent tissues (P<0.05). The positive rates of hTERT and MTA1 in esophageal cancer with low differentiation, TNM stage III + IV, lymph node metastasis were higher than those in high differentiation, TNM stage I + II, no lymph node metastasis(P<0.05). There was no significant difference in the positive rates of hTERT and MTA1 in esophageal cancer with different gender, age, the largest diameter of focus, tumor location, pathological type (P>0.05). Spearman correlation analysis showed that the expression of hTERT was positively correlated with the expression of MTA1 (r=0.645, P=0.000). After 36 months of follow-up, the survival rate of 33 patients was 41.25% (33/80). The survival rate and median survival time of esophageal cancer patients with hTERT negative and MTA1 negative were 64.29%(9/14), 23.6 months, 60.87% (14/23) and 24.9 months, respectively, which were significantly better than those of patients with hTERT positive and MTA1 positive in 36.36% (24/66), 19.2 months, 33.33% (19/57) and 18.5 months (P<0.05). Conclusion: There are abnormal high expression of hTERT and MTA1 in esophageal cancer. The expression of hTERT and MTA1 is closely related to tissue differentiation, TNM stage and lymph node metastasis of esophageal cancer, and its expression is closely related to the survival period of esophageal cancer patients. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To evaluate The value of ultrasonography in evaluating the survival of patients with severe acute left ventricular systolic dysfunction. Methods: 153 patients with severe acute left ventricular systolic dysfunction in ICU of our hospital from October 2015 to October 2016 were selected s as the research object, and they were divided into whole diffuse heart inhibition, left diffuse inhibition, coronary artery related segment inhibition, coronary artery non-related segment inhibition were according to echocardiography result. Their mortality rates at 1 month were recorded. Results: Among 153 patients with severe acute left ventricular systolic insufficiency, cardiac ultrasound showed total diffuse inhibition in 45 cases, left ventricular diffuse inhibition in 35 cases, coronary artery related segmental inhibition in 36 cases, and non-coronary artery related segmental inhibition in 37 cases. The one-month mortality of patients with whole-heart diffuse inhibition was 33.3%, that of those with left-heart diffuse inhibition was 14.3%, that of those with coronary artery segmental inhibition was 13.9%, and that of those without coronary artery segmental inhibition was 8.1%. The difference between the two groups was statistically significant (P<0.05). The mortality of patients with left ventricular diastolic dysfunction combined with foundation was 62.5%, higher than that of those without foundation diastolic dysfunction (13.5%), and the difference was statistically significant (13.5%, P<0.05). Conclusion: Echocardiography could help to assess the survival condition of patients with severe acute left ventricular systolic dysfunction, which is worthy of clinical application. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)